Program
daprodustat
Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.
Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 320 open or running | phase 3since Jun 2, 2016 | Jun 16, 2011 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 3since Dec 10, 2025 | Dec 10, 2025 | May 2027phase 3 · NCT07300111 |
Also a collaborator on its studies: q2-solutions, quintiles-inc, hemocue and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Jun 16, 2011.
- Feb 11, 2016Phase 2 study in AnemiaGlaxoSmithKline · NCT02689206 · 103 enrolled · United States, Canada, Germany and more
- Jun 2, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02791763 · 355 enrolled · Japan
- Jul 8, 2016Phase 3 study in AnemiaGlaxoSmithKline · NCT02829320 · 28 enrolled · Japan
- Aug 19, 20162 phase 3 studies in AnemiaGlaxoSmithKline · NCT02876835, NCT02879305
- Jan 20, 2017Phase 2 study in AnemiaGlaxoSmithKline · NCT03029247 · 105 enrolled · United States
- Jan 20, 2017Phase 3 study in AnemiaGlaxoSmithKline · NCT03029208 · 312 enrolled · United States, Argentina, Australia and more
- Jul 17, 20172 phase 1 studies in AnemiaGlaxoSmithKline · NCT03239522, NCT03223337
- Jan 8, 20182 phase 3 studies in AnemiaGlaxoSmithKline · NCT03409107, NCT03400033
- Feb 20, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03446612 · 6 enrolled · United Kingdom
- Mar 1, 2018Phase 2 study in AnemiaGlaxoSmithKline · NCT03457701 · 15 enrolled · United States
- Apr 4, 2018Phase 1 study in AnemiaGlaxoSmithKline · NCT03493386 · 64 enrolled · Japan
- Nov 18, 2020Phase 1 study in AnemiaGlaxoSmithKline · NCT04640311 · 259 enrolled · United States
- Jan 4, 2023Phase 3 study in AnemiaGlaxoSmithKline · NCT05682326 · 4 enrolled · Japan, South Korea
- Dec 10, 2025Qilu Pharmaceutical's first study: phase 3 study in AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07300111 · 100 planned
Ahead
- May 2027Primary completion: phase 3 study in AnemiaQilu Pharmaceutical · NCT07300111
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07300111Anemia | 3 | Not yet recruiting | Qilu Pharmaceutical | May 2027 | 100 |
| NCT05682326Anemia · Japan, South Korea | 3 | Completed | GlaxoSmithKline | Oct 18, 2024 | 4 |
| NCT04640311Anemia · United States | 1 | Completed | GlaxoSmithKline | May 18, 2021 | 259 |
| NCT03493386Anemia · Japan | 1 | Completed | GlaxoSmithKline | Jun 9, 2018 | 64 |
| NCT03457701Anemia · United States | 2 | Completed | GlaxoSmithKline | Jul 5, 2022 | 15 |
| NCT03446612Anemia · United Kingdom | 2 | Terminated | GlaxoSmithKline | May 29, 2019 | 6 |
| NCT03409107Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Oct 7, 2020 | 614 |
| NCT03400033Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jun 19, 2020 | 407 |
| NCT03223337Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 20, 2018 | 37 |
| NCT03239522Anemia · United Kingdom | 1 | Completed | GlaxoSmithKline | Nov 28, 2017 | 6 |
| NCT03029247Anemia · United States | 2 | Completed | GlaxoSmithKline | Jul 9, 2020 | 105 |
| NCT03029208Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Sep 24, 2020 | 312 |
| NCT02879305Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Nov 9, 2020 | 2,964 |
| NCT02876835Anemia · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 19, 2021 | 3,872 |
| NCT02829320Anemia · Japan | 3 | Completed | GlaxoSmithKline | May 16, 2017 | 28 |
| NCT02791763Anemia · Japan | 3 | Completed | GlaxoSmithKline | Oct 26, 2018 | 355 |
| NCT02689206Anemia · United States, Canada, Germany and more | 2 | Completed | GlaxoSmithKline | Jan 25, 2017 | 103 |
| NCT02371603Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 12, 2015 | 70 |
| NCT02293148Anemia · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2015 | 61 |
| NCT02231190Tendon Injuries · United States | 1 | Completed | GlaxoSmithKline | Jun 12, 2015 | 26 |
| NCT02243306Anemia · United States | 1 | Completed | GlaxoSmithKline | May 10, 2017 | 8 |
| NCT02075463Anemia · United States | 2 | Terminated | GlaxoSmithKline | Mar 16, 2016 | 15 |
| NCT02019719Anemia · Japan | 2 | Completed | GlaxoSmithKline | Aug 6, 2014 | 97 |
| NCT01977573Anemia · United States, Australia, Canada and more | 2 | Completed | GlaxoSmithKline | May 1, 2015 | 252 |
| NCT01977482Anemia · United States, Australia, Canada and more | 2 | Completed | GlaxoSmithKline | Feb 1, 2015 | 216 |
| NCT01920594Surgical Procedures · United States, Canada | 2 | Completed | GlaxoSmithKline | Oct 8, 2014 | 57 |
| NCT01831804Diabetic Foot · United States | 1 | Completed | GlaxoSmithKline | Feb 10, 2017 | 65 |
| NCT01673555Anemia · United States | 1 | Completed | GlaxoSmithKline | Nov 19, 2012 | 49 |
| NCT02135848Peripheral Vascular Diseases · United States | 2 | Completed | GlaxoSmithKline | Nov 1, 2011 | 46 |
| NCT01587924Anemia · United States, Canada, Denmark and more | 2 | Completed | GlaxoSmithKline | May 27, 2013 | 80 |
| NCT01587898Anemia · United States, Canada, Germany | 2 | Completed | GlaxoSmithKline | May 7, 2013 | 72 |
| NCT01406340Anemia · United States | 1 | Terminated | GlaxoSmithKline | Aug 31, 2013 | 22 |
| NCT01376232Anemia · India | 1 | Completed | GlaxoSmithKline | Dec 20, 2010 | 23 |
How it is read
Names in the registry
- “GSK1278863”, 15 entries
- “Daprodustat”, 9 entries
- “Daprodustat (GSK1278863)”, 2 entries
- “Daprodustat tablets”, 1 entry
- “1 to 4 mg tablets of GSK1278863”, 1 entry
Codes read as this program: GSK1278863.
Conditions, from the studies’ own filings
- Anemia, 29 studies
- Diabetic Foot, 1 study
- Peripheral Vascular Diseases, 1 study
- Tendon Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.